Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Single-Cell Diagnostics Advocated for Breast Cancer Subtyping

By LabMedica International staff writers
Posted on 06 Nov 2017
In an opinion article based their analysis of studies, two medical researchers argue that women diagnosed with breast cancer (BC) would likely benefit from treatment based also on identifying the molecular subtype of different cells within their tumors, in addition to current molecular and histopathology testing of collections of tumor cells.

They discuss the growing consensus that a tumor can have cells of multiple origins and respond variably to treatment. More...
The authors advocate for development of more accurate diagnostics to capture molecular irregularities between cells within a tumor.

"Breast tumors are moving targets because they are really versatile," said Jun-Lin Guan, professor at University of Cincinnati College of Medicine (Cincinnati, OH; USA), who co-authored the paper with postdoctoral fellow Syn Kok Yeo, "If you use a treatment that's targeting one subtype, which kills one type of breast cancer, often the other kind will actually expand. That defeats the purpose of treatment."

BC cells differ by the types of molecular markers (genetic or biochemical, some of which are found on their surface) that physicians can have tested to understand the characteristics of a patient's cancer to help devise an optimal treatment strategy. For example, women with the HER2+ BC subtype generally have a poorer prognosis than those with the luminal A tumors because of how quickly the cells multiply. Often tumor samples are taken and screened for the most common markers present, but Prof. Guan and Dr. Yeo's analysis of human and rodent studies raises the possibility that overlapping subtypes are being missed.

The researchers put forward the hypothesis that the co-existence of distinct BC subtypes within tumors happens because a fraction of BC cells retain many stem cell -like qualities and thus reserve the capability to easily change. This has been observed in human cancer cells and in rodent studies but has yet to be confirmed in patients. Single-cell analysis could assess whether this problem is common or rare in humans.

They advocate for diagnostic testing to be combined with single-cell technologies, in which individual cells are screened (via mass spectrometry, DNA sequencing, etc) for molecular markers. However, single-cell approaches are currently expensive and require specialized expertise, so they are not yet realistic for regular patient screenings.

"What we're talking about is still not widely used in practice--there's a gap between basic cancer research and the clinics that do the diagnoses," Prof. Guan said, "However, single-cell technologies are advancing very quickly, so it's possible that we can see them being used in the near future."

The paper, by Yeo SK and Guan J-L, was published October 24, 2017, in the journal Trends in Cancer.

Related Links:
University of Cincinnati College of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.